$2.14
-0.02 (-0.93%)
Open$2.15
Previous Close$2.16
Day High$2.19
Day Low$2.13
52W High$3.24
52W Low$1.30
Volume—
Avg Volume288.2K
Market Cap195.73M
P/E Ratio5.62
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+2,071.0% upside
Current
$2.14
$2.14
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 35.75M | 14.58M | 13.34M |
| Net Income | 35.28M | 2.88M | 3.22M |
| Profit Margin | -56.1% | 19.8% | 24.2% |
| EBITDA | 31.75M | 4.55M | 4.43M |
| Free Cash Flow | — | 4.06M | 3.77M |
| Rev Growth | — | -8.4% | -7.1% |
| Debt/Equity | — | 0.65 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |